Many studies in the field have focused on identification of activation of Nrf2 as ‘bad’ for cancer patients during the course of chemotherapy45, as evidenced by our finding that modulation of the Nrf2-mediated response affected the resistant carcinogenic process in response to chemotherapeutic agents. The gene discussed is NFE2L2; the disease is cancer.